At CRISP-HR Therapeutics, our goal is develop technology to allow non-toxic, high efficiency error-free genetic engineering at any site, of any size, in any genome, and in any organism.

At CRISP-HR Therapeutics, we have addressed these limitations by developing a next generation CRISPR based genetic engineering platform: Cas9-HR. Cas9-HR directs cells to use error-free rather than error-prone pathways, which we have demonstrated can dramatically decrease cellular toxicity while simultaneously increasing error-free editing efficiency.

Ultimately, we believe our Cas9-HR platform solves major problems plaguing first generation CRISPR/Cas9 systems. We look forward to developing a wide variety of cellular therapeutics using the platform, to improve patient outcomes, quality of life, and overall human wellbeing.

Company Information

April 20, 2022